The 3rd TIGIT Axis Therapies Summit returns to unite large pharma, innovative biotechs and pioneering academics to discuss the full range of next-generation TIGIT axis targeted drug modalities and maximize TIGIT-axis targeting in the solid tumor, blood cancer and non-oncology setting.
Covering deciphering the mechanistic intricacies underlying TIGIT axis signaling, defining combination partners that improve efficacy and strengthen TIGIT targeted pipelines, exploring novel drug designs in terms of Fc functionality and IgG type, identifying molecular signatures relevant to the tumor microenvironment and periphery to incorporating unique pharmacology properties into trial design, this is your guide to addressing the unique challenges of TIGIT axis targeted drug development.
This year’s sharp two-day agenda leans into the clinical headwinds faced by so many immune checkpoint targets. As the space regroups, join the likes of Compugen, iTeos Therapeutics, Genentech, Mereo BioPharma, Gilead Sciences, Nectin Therapeutics, Shattuck Labs, Graphite Bio, GlaxoSmithKline and many more to build meaningful partnerships and maximize the clinical and commercial success of the next generation of TIGIT axis targeted drugs.
View the full agenda here.
The post 3rd TIGIT Axis Therapies Summit appeared first on .
